Participant-perceived understanding and perspectives on pharmacogenomics

The Mayo Clinic RIGHT protocol (Right Drug, Right Dose, Right Time)

Janet E Olson, Carolyn R. Rohrer Vitek, Elizabeth J. Bell, Michaela E. McGree, Debra J. Jacobson, Jennifer St. Sauver, Pedro Caraballo, Joan Griffin, Veronique Lee Roger, Suzette J Bielinski

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose:To examine predictors of understanding preemptive CYP2D6 pharmacogenomics test results and to identify key features required to improve future educational efforts of preemptive pharmacogenomics testing.Methods:One thousand ten participants were surveyed after receiving preemptive CYP2D6 pharmacogenomics test results.Results:Eighty-six percent (n = 869) of patients responded. Of the responders, 98% were white and 55% were female; 57% had 4 years or more of post-secondary education and an average age of 58.9 ± 5.5 years. Twenty-six percent said that they only somewhat understood their results and 7% reported they did not understand them at all. Only education predicted understanding. The most common suggestion for improvement was the use of layperson's terms when reporting results. In addition, responders suggested that results should be personalized by referring to medications that they were currently using. Of those reporting imperfect drug adherence, most (91%) reported they would be more likely to use medication as prescribed if pharmacogenomic information was used to help select the drug or dose.Conclusion:Despite great efforts to simplify pharmacogenomic results (or because of them), approximately one-Third of responders did not understand their results. Future efforts need to provide more examples and tailor results to the individual. Incorporation of pharmacogenomics is likely to improve medication adherence.Genet Med advance online publication 05 January 2017.

Original languageEnglish (US)
Pages (from-to)819-825
Number of pages7
JournalGenetics in Medicine
Volume19
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Pharmacogenetics
Cytochrome P-450 CYP2D6
Pharmaceutical Preparations
Viverridae
Education
Medication Adherence
Publications

Keywords

  • CYP2D6
  • patient understanding
  • pharmacogenomics
  • preemptive genotyping
  • return Of Results

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Participant-perceived understanding and perspectives on pharmacogenomics : The Mayo Clinic RIGHT protocol (Right Drug, Right Dose, Right Time). / Olson, Janet E; Rohrer Vitek, Carolyn R.; Bell, Elizabeth J.; McGree, Michaela E.; Jacobson, Debra J.; St. Sauver, Jennifer; Caraballo, Pedro; Griffin, Joan; Roger, Veronique Lee; Bielinski, Suzette J.

In: Genetics in Medicine, Vol. 19, No. 7, 01.07.2017, p. 819-825.

Research output: Contribution to journalArticle

@article{4ebc379cea9e4e239c7917647ff4b128,
title = "Participant-perceived understanding and perspectives on pharmacogenomics: The Mayo Clinic RIGHT protocol (Right Drug, Right Dose, Right Time)",
abstract = "Purpose:To examine predictors of understanding preemptive CYP2D6 pharmacogenomics test results and to identify key features required to improve future educational efforts of preemptive pharmacogenomics testing.Methods:One thousand ten participants were surveyed after receiving preemptive CYP2D6 pharmacogenomics test results.Results:Eighty-six percent (n = 869) of patients responded. Of the responders, 98{\%} were white and 55{\%} were female; 57{\%} had 4 years or more of post-secondary education and an average age of 58.9 ± 5.5 years. Twenty-six percent said that they only somewhat understood their results and 7{\%} reported they did not understand them at all. Only education predicted understanding. The most common suggestion for improvement was the use of layperson's terms when reporting results. In addition, responders suggested that results should be personalized by referring to medications that they were currently using. Of those reporting imperfect drug adherence, most (91{\%}) reported they would be more likely to use medication as prescribed if pharmacogenomic information was used to help select the drug or dose.Conclusion:Despite great efforts to simplify pharmacogenomic results (or because of them), approximately one-Third of responders did not understand their results. Future efforts need to provide more examples and tailor results to the individual. Incorporation of pharmacogenomics is likely to improve medication adherence.Genet Med advance online publication 05 January 2017.",
keywords = "CYP2D6, patient understanding, pharmacogenomics, preemptive genotyping, return Of Results",
author = "Olson, {Janet E} and {Rohrer Vitek}, {Carolyn R.} and Bell, {Elizabeth J.} and McGree, {Michaela E.} and Jacobson, {Debra J.} and {St. Sauver}, Jennifer and Pedro Caraballo and Joan Griffin and Roger, {Veronique Lee} and Bielinski, {Suzette J}",
year = "2017",
month = "7",
day = "1",
doi = "10.1038/gim.2016.192",
language = "English (US)",
volume = "19",
pages = "819--825",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Participant-perceived understanding and perspectives on pharmacogenomics

T2 - The Mayo Clinic RIGHT protocol (Right Drug, Right Dose, Right Time)

AU - Olson, Janet E

AU - Rohrer Vitek, Carolyn R.

AU - Bell, Elizabeth J.

AU - McGree, Michaela E.

AU - Jacobson, Debra J.

AU - St. Sauver, Jennifer

AU - Caraballo, Pedro

AU - Griffin, Joan

AU - Roger, Veronique Lee

AU - Bielinski, Suzette J

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Purpose:To examine predictors of understanding preemptive CYP2D6 pharmacogenomics test results and to identify key features required to improve future educational efforts of preemptive pharmacogenomics testing.Methods:One thousand ten participants were surveyed after receiving preemptive CYP2D6 pharmacogenomics test results.Results:Eighty-six percent (n = 869) of patients responded. Of the responders, 98% were white and 55% were female; 57% had 4 years or more of post-secondary education and an average age of 58.9 ± 5.5 years. Twenty-six percent said that they only somewhat understood their results and 7% reported they did not understand them at all. Only education predicted understanding. The most common suggestion for improvement was the use of layperson's terms when reporting results. In addition, responders suggested that results should be personalized by referring to medications that they were currently using. Of those reporting imperfect drug adherence, most (91%) reported they would be more likely to use medication as prescribed if pharmacogenomic information was used to help select the drug or dose.Conclusion:Despite great efforts to simplify pharmacogenomic results (or because of them), approximately one-Third of responders did not understand their results. Future efforts need to provide more examples and tailor results to the individual. Incorporation of pharmacogenomics is likely to improve medication adherence.Genet Med advance online publication 05 January 2017.

AB - Purpose:To examine predictors of understanding preemptive CYP2D6 pharmacogenomics test results and to identify key features required to improve future educational efforts of preemptive pharmacogenomics testing.Methods:One thousand ten participants were surveyed after receiving preemptive CYP2D6 pharmacogenomics test results.Results:Eighty-six percent (n = 869) of patients responded. Of the responders, 98% were white and 55% were female; 57% had 4 years or more of post-secondary education and an average age of 58.9 ± 5.5 years. Twenty-six percent said that they only somewhat understood their results and 7% reported they did not understand them at all. Only education predicted understanding. The most common suggestion for improvement was the use of layperson's terms when reporting results. In addition, responders suggested that results should be personalized by referring to medications that they were currently using. Of those reporting imperfect drug adherence, most (91%) reported they would be more likely to use medication as prescribed if pharmacogenomic information was used to help select the drug or dose.Conclusion:Despite great efforts to simplify pharmacogenomic results (or because of them), approximately one-Third of responders did not understand their results. Future efforts need to provide more examples and tailor results to the individual. Incorporation of pharmacogenomics is likely to improve medication adherence.Genet Med advance online publication 05 January 2017.

KW - CYP2D6

KW - patient understanding

KW - pharmacogenomics

KW - preemptive genotyping

KW - return Of Results

UR - http://www.scopus.com/inward/record.url?scp=85024111670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024111670&partnerID=8YFLogxK

U2 - 10.1038/gim.2016.192

DO - 10.1038/gim.2016.192

M3 - Article

VL - 19

SP - 819

EP - 825

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 7

ER -